BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
PreveCeutical Medical (OTCQB: PRVCF) has announced the appointment of Dr. Kamal Albarazanji as Senior Director of Metabolic Research at its subsidiary BioGene Therapeutics, effective August 18, 2025. Dr. Albarazanji brings extensive experience in metabolic research, having previously served as a Senior Scientist in Cardiovascular & Metabolic Diseases.
Dr. Albarazanji's background includes significant work at SmithKline Beecham (now GSK) on various therapeutic programs, including renin inhibitors and insulin sensitizers. He holds multiple patents and has authored over 20 peer-reviewed publications in prestigious journals. His expertise spans in vivo pharmacology, target validation, and translational research, with particular focus on metabolic diseases, obesity, and diabetes treatments.
PreveCeutical Medical (OTCQB: PRVCF) ha nominato il Dott. Kamal Albarazanji Senior Director of Metabolic Research presso la sua controllata BioGene Therapeutics, a partire dal 18 agosto 2025. Il dott. Albarazanji porta con sé una vasta esperienza nella ricerca metabolica, avendo ricoperto in precedenza il ruolo di Senior Scientist in Cardiovascular & Metabolic Diseases.
Nel corso della sua carriera ha svolto attività rilevanti in SmithKline Beecham (oggi GSK) su diversi programmi terapeutici, tra cui inibitori della renina e sensibilizzanti dell’insulina. È titolare di numerosi brevetti e autore di oltre 20 pubblicazioni peer-reviewed su riviste di rilievo. Le sue competenze comprendono farmacologia in vivo, validazione di target e ricerca traslazionale, con un focus particolare su malattie metaboliche, obesità e terapie per il diabete.
PreveCeutical Medical (OTCQB: PRVCF) ha anunciado el nombramiento del Dr. Kamal Albarazanji como Senior Director of Metabolic Research en su filial BioGene Therapeutics, con efecto desde el 18 de agosto de 2025. El Dr. Albarazanji aporta una amplia experiencia en investigación metabólica, habiendo sido anteriormente Senior Scientist en Cardiovascular & Metabolic Diseases.
Su trayectoria incluye trabajo relevante en SmithKline Beecham (ahora GSK) en diversos programas terapéuticos, como inhibidores de la renina y sensibilizadores de la insulina. Posee múltiples patentes y es autor de más de 20 publicaciones revisadas por pares en revistas de prestigio. Su experiencia abarca farmacología in vivo, validación de dianas e investigación traslacional, con especial interés en enfermedades metabólicas, obesidad y tratamientos para la diabetes.
PreveCeutical Medical (OTCQB: PRVCF)는 자회사 BioGene Therapeutics의 대사 연구 총괄 책임자(Senior Director of Metabolic Research)로 닥터 카말 알바라잔지(Dr. Kamal Albarazanji)를 2025년 8월 18일부로 임명했다고 발표했습니다. 알바라잔지 박사는 대사 연구 분야에서 풍부한 경험을 보유하고 있으며, 이전에는 심혈관 및 대사 질환 부문에서 수석 과학자(Senior Scientist)로 재직했습니다.
그는 SmithKline Beecham(현 GSK)에서 레닌 억제제와 인슐린 감수성 개선제 등 다양한 치료제 프로그램에 참여한 경력이 있습니다. 다수의 특허를 보유하고 있으며, 권위 있는 학술지에 20편 이상의 동료 심사 논문(peer-reviewed publications)을 게재했습니다. in vivo 약리학, 타깃 검증 및 중개연구(translational research)를 포함한 전문성을 갖추고 있으며, 대사 질환, 비만 및 당뇨병 치료에 특히 중점을 두고 있습니다.
PreveCeutical Medical (OTCQB: PRVCF) a annoncé la nomination du Dr Kamal Albarazanji au poste de Senior Director of Metabolic Research au sein de sa filiale BioGene Therapeutics, avec prise de fonction le 18 août 2025. Le Dr Albarazanji apporte une vaste expérience en recherche métabolique, ayant précédemment occupé le poste de Senior Scientist en Cardiovascular & Metabolic Diseases.
Parmi ses expériences figure un travail important chez SmithKline Beecham (aujourd’hui GSK) sur plusieurs programmes thérapeutiques, notamment des inhibiteurs de la rénine et des sensibilisateurs à l’insuline. Il est titulaire de plusieurs brevets et auteur de plus de 20 publications évaluées par des pairs dans des revues de renom. Son expertise couvre la pharmacologie in vivo, la validation de cibles et la recherche translationnelle, avec un accent particulier sur les maladies métaboliques, l’obésité et les traitements du diabète.
PreveCeutical Medical (OTCQB: PRVCF) hat die Ernennung von Dr. Kamal Albarazanji zum Senior Director of Metabolic Research bei der Tochtergesellschaft BioGene Therapeutics mit Wirkung vom 18. August 2025 bekannt gegeben. Dr. Albarazanji bringt umfangreiche Erfahrung in der Metabolforschung mit und war zuvor als Senior Scientist im Bereich Cardiovascular & Metabolic Diseases tätig.
Sein Werdegang umfasst bedeutende Arbeiten bei SmithKline Beecham (heute GSK) an verschiedenen Therapieprogrammen, darunter Renin-Inhibitoren und Insulinsensitizer. Er hält mehrere Patente und ist Autor von über 20 peer-reviewed Veröffentlichungen in renommierten Fachzeitschriften. Seine Expertise umfasst in vivo-Pharmakologie, Target-Validierung und translationale Forschung mit besonderem Fokus auf Stoffwechselerkrankungen, Adipositas und Diabetesbehandlungen.
- Appointment of highly experienced scientist with expertise in metabolic research and drug development
- Addition of proven leadership in advancing compounds from discovery to clinical trials
- Strong track record with 20+ peer-reviewed publications and multiple patents
- None.
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on 18 August, 2025.
Dr. Albarazanji brings a wealth of expertise in in vivo pharmacology, target validation, and translational research. Most recently, he served as a Senior Scientist in Cardiovascular & Metabolic Diseases at a leading pharmaceutical company, where he led programs on enteropeptidase inhibitors for metabolic diseases and AMPK activators for acute kidney injury. His career spans notable roles at SmithKline Beecham (now GSK), where he contributed to groundbreaking work on renin inhibitors for hypertension, insulin sensitizers like Avandia, and neuropeptide programs for obesity. Dr. Albarazanji has championed multiple novel targets, including GPR39 agonists, muscarinic M3 receptor antagonists, and vasopressin V1b antagonists, resulting in significant advancements in weight loss, glucose metabolism, and gastrointestinal hormone regulation.
A prolific researcher, Dr. Albarazanji holds numerous patents and has authored over 20 peer-reviewed manuscripts in prestigious journals such as Diabetes, Journal of Pharmacology and Experimental Therapeutics, and American Journal of Physiology. His work has been presented at major conferences, including the American Diabetes Association and Keystone Symposia, and he has been instrumental in advancing compounds from discovery to clinical trials.
"We are thrilled to welcome Dr. Albarazanji to BioGene Therapeutics," said Stephen Van Deventer, Chairman & CEO of BioGene Therapeutics Inc. "His deep knowledge in metabolic disease biology and proven track record in leading cross-functional teams will accelerate our pipeline of innovative therapeutics. Kamal's vision aligns perfectly with our mission to address unmet needs in obesity and diabetes through cutting-edge science."
"I am excited to join BioGene Therapeutics at this pivotal time," said Dr. Albarazanji. "The company's commitment to leveraging novel mechanisms for metabolic health resonates with my passion for translating research into life-changing treatments. I look forward to collaborating with the talented team to advance our programs and deliver meaningful outcomes for patients."
Dr. Albarazanji earned his Ph.D. in Physiology from the University of Manchester and began his career with foundational research on neuroendocrine regulation. His appointment is effective immediately.
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263042
FAQ
Who is Dr. Kamal Albarazanji and what is his new role at PRVCF?
What is Dr. Albarazanji's experience in pharmaceutical research?
How will Dr. Albarazanji's appointment impact PreveCeutical's research direction?
What are Dr. Albarazanji's key research achievements?
